The US FDA advises sponsors to look at a variety of sources to determine if a Risk Evaluation and Mitigation Strategy (REMS) is meeting its goal of lessening a drug's risks, including drug utilization data, stakeholder surveys and observational and epidemiology data.
The agency describes how to develop a REMS Assessment Plan in a draft guidance released Jan. 24. The document also discusses assessing the impact of REMS on patient access...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?